Evidence map›Paper›PMID 32771089›Full record

ArticleThe lancet. HIV2020

Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models.

Britta L Jewell, Edinah Mudimu, John Stover, Debra Ten Brink, Andrew N Phillips, Jennifer A Smith, Rowan Martin-Hughes, Yu Teng, Robert Glaubius, Severin Guy Mahiane and 10 more

Open access · hybridAbstract read
In one paragraph

Article in The lancet. HIV, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 252 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
252citing papers in PubMed, 8 pooled it
104.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

252 citing papers in PubMed, 8 syntheses or guidelines pooled it, 414 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

192 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 7 countries.

Britta L JewellMedical Research Council Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, London, UK.
Edinah MudimuDepartment of Decision Sciences, University of South Africa, Pretoria, South Africa.
John StoverAvenir Health, Glastonbury, CT, USA.
Debra Ten BrinkBurnet Institute, Melbourne, VIC, Australia.
Andrew N PhillipsInstitute for Global Health, University College London, London, UK. Electronic address: andrew.phillips@ucl.ac.uk.
Jennifer A SmithMedical Research Council Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, London, UK.
Rowan Martin-HughesBurnet Institute, Melbourne, VIC, Australia.
Yu TengAvenir Health, Glastonbury, CT, USA.
Robert GlaubiusAvenir Health, Glastonbury, CT, USA.
Severin Guy MahianeAvenir Health, Glastonbury, CT, USA.
Loveleen Bansi-MatharuInstitute for Global Health, University College London, London, UK.
Isaac TaramusiNational AIDS Council of Zimbabwe, Harare, Zimbabwe.
Newton ChagomaNational AIDS Council of Malawi, Lilongwe, Malawi.
Michelle MorrisonBill & Melinda Gates Foundation, Seattle, WA, USA.
Meg DohertyWHO, Geneva, Switzerland.
Kimberly MarshUNAIDS, Geneva, Switzerland.
Anna BershteynNew York University School of Medicine, New York, NY, USA.
Timothy B HallettMedical Research Council Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, London, UK.
Sherrie L KellyBurnet Institute, Melbourne, VIC, Australia.
HIV Modelling Consortium
Avenir Health · USBurnet Institute · AUMedical Research Council · GBUniversity College London · GBBill & Melinda Gates Foundation · USJoint United Nations Programme on HIV/AIDS · CHNational AIDS Commission · MWNational AIDS Council · ZWNew York University · USUniversity of South Africa · ZAWorld Health Organization · CH

Funding

Medical Research Council MC_PC_19012Medical Research Council MR/R015600/1World Health Organization 001
6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic could lead to disruptions to provision of HIV services for people living with HIV and those at risk of acquiring HIV in sub-Saharan Africa, where UNAIDS estimated that more than two-thirds of the approximately 38 million people living with HIV resided in 2018. We aimed to predict the potential effects of such disruptions on HIV-related deaths and new infections in sub-Saharan Africa.

methodsIn this modelling study, we used five well described models of HIV epidemics (Goals, Optima HIV, HIV Synthesis, an Imperial College London model, and Epidemiological MODeling software [EMOD]) to estimate the effect of various potential disruptions to HIV prevention, testing, and treatment services on HIV-related deaths and new infections in sub-Saharan Africa lasting 6 months over 1 year from April 1, 2020. We considered scenarios in which disruptions affected 20%, 50%, and 100% of the population.

findingsA 6-month interruption of supply of antiretroviral therapy (ART) drugs across 50% of the population of people living with HIV who are on treatment would be expected to lead to a 1·63 times (median across models; range 1·39-1·87) increase in HIV-related deaths over a 1-year period compared with no disruption. In sub-Saharan Africa, this increase amounts to a median excess of HIV deaths, across all model estimates, of 296 000 (range 229 023-420 000) if such a high level of disruption occurred. Interruption of ART would increase mother-to-child transmission of HIV by approximately 1·6 times. Although an interruption in the supply of ART drugs would have the largest impact of any potential disruptions, effects of poorer clinical care due to overstretched health facilities, interruptions of supply of other drugs such as co-trimoxazole, and suspension of HIV testing would all have a substantial effect on population-level mortality (up to a 1·06 times increase in HIV-related deaths over a 1-year period due to disruptions affecting 50% of the population compared with no disruption). Interruption to condom supplies and peer education would make populations more susceptible to increases in HIV incidence, although physical distancing measures could lead to reductions in risky sexual behaviour (up to 1·19 times increase in new HIV infections over a 1-year period if 50% of people are affected).

interpretationDuring the COVID-19 pandemic, the primary priority for governments, donors, suppliers, and communities should focus on maintaining uninterrupted supply of ART drugs for people with HIV to avoid additional HIV-related deaths. The provision of other HIV prevention measures is also important to prevent any increase in HIV incidence.

fundingBill & Melinda Gates Foundation.

Indexed as

Models, StatisticalPandemicsAfrica South of the SaharaAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBetacoronavirusCondomsCoronavirus InfectionsCOVID-19FemaleGlobal HealthHIV-1HIV InfectionsHumansIncidenceInfant, NewbornAnti-HIV Agents

Identifiers

PMID32771089
PMCPMC7482434
OpenAlexW3047456007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.